Department of Pathology, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA.
J Mol Med (Berl). 2010 Jun;88(6):577-88. doi: 10.1007/s00109-010-0602-9. Epub 2010 Mar 12.
Human CD4(+)CD25(high)FOXP3(+) T regulatory cells (Treg) can suppress responder T cell (RC) functions by various mechanisms. In co-cultures of Treg and autologous activated RC, both cell subsets up-regulate the expression of granzymes and perforin, which might contribute to Treg-mediated suppression. Here, we investigate the sensitivity and resistance of Treg and RC to granzyme/perforin-mediated death. CD4(+)CD25(neg) RC were single cell-sorted from the peripheral blood of 25 cancer patients and 15 normal controls. These RC were carboxyfluorescein diacetate succinimidyl ester (CFSE) labeled and co-cultured with autologous CD4(+)CD25(high)FOXP3(+) Treg +/- 150 or +/-1,000 IU/mL of interleukin-2 (IL-2) to evaluate suppression of RC proliferation. In addition, survival of the cells co-cultured for 24 h and 5 days was measured using a flow-based cytotoxicity assay. Freshly isolated Treg and RC expressed granzyme A (GrA), granzyme B (GrB), and perforin. Percentages of positive cells were higher in cancer patients than controls (p < 0.01) and increased upon OKT3 and IL-2 stimulation. Treg, co-cultured with RC at 150 IU/mL of IL-2, no longer expressed cytotoxins and became susceptible to RC-mediated, granzyme/perforin-dependent death. However, in co-cultures with 1,000 IU/mL of IL-2, Treg became resistant to apoptosis and induced GrB-dependent, perforin-independent death of RC. When the GrB inhibitor I or GrB-specific and GrA-specific small inhibitory ribonucleic acids were used to block the granzyme pathway in Treg, RC death, and Treg-mediated suppression of RC, proliferation were significantly inhibited. Human CD4(+)CD25(high) Treg and CD4(+)CD25(neg) RC reciprocally regulate death/growth arrest by differentially utilizing the granzyme-perforin pathway depending on IL-2 concentrations.
人类 CD4(+)CD25(high)FOXP3(+)调节性 T 细胞(Treg)可以通过多种机制抑制应答性 T 细胞(RC)的功能。在 Treg 和自体激活的 RC 的共培养物中,这两个细胞亚群都上调颗粒酶和穿孔素的表达,这可能有助于 Treg 介导的抑制。在这里,我们研究了 Treg 和 RC 对颗粒酶/穿孔素介导的死亡的敏感性和抗性。从 25 名癌症患者和 15 名正常对照者的外周血中单细胞分选 CD4(+)CD25(neg)RC。这些 RC 被羧基荧光素二乙酸琥珀酰亚胺酯(CFSE)标记,并与自体 CD4(+)CD25(high)FOXP3(+)Treg +/-150 或 +/-1,000 IU/mL 白细胞介素-2(IL-2)共培养,以评估 RC 增殖的抑制。此外,使用基于流式细胞术的细胞毒性测定法测量共培养 24 小时和 5 天后细胞的存活率。新鲜分离的 Treg 和 RC 表达颗粒酶 A(GrA)、颗粒酶 B(GrB)和穿孔素。与对照组相比,癌症患者的阳性细胞百分比更高(p < 0.01),并且在 OKT3 和 IL-2 刺激后增加。Treg 在 150 IU/mL IL-2 与 RC 共培养时不再表达细胞毒素,并对 RC 介导的、颗粒酶/穿孔素依赖性死亡敏感。然而,在 1,000 IU/mL IL-2 的共培养物中,Treg 对细胞凋亡具有抗性,并诱导 RC 的 GrB 依赖性、穿孔素非依赖性死亡。当使用 GrB 抑制剂 I 或 GrB 特异性和 GrA 特异性小干扰 RNA 阻断 Treg 中的颗粒酶途径时,RC 死亡和 Treg 对 RC 增殖的抑制作用显著抑制。人类 CD4(+)CD25(high)Treg 和 CD4(+)CD25(neg)RC 通过根据 IL-2 浓度差异利用颗粒酶-穿孔素途径来相互调节死亡/生长阻滞。
Front Cell Dev Biol. 2022-11-16
Front Immunol. 2017-1-23
Immunotargets Ther. 2015-8-5
Cancer Microenviron. 2015-12
Immunity. 2009-5
Immunol Rev. 2008-12
Nat Rev Immunol. 2007-7